🔎 Trials Near Me

Utama › Kanser Pundi Kencing › California › Irvine

Kajian klinikal Kanser Pundi Kencing di Irvine, CA

11 kajian untuk Kanser Pundi Kencing sedang mencari peserta di lokasi dalam dan sekitar Irvine (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

Mengambil pesertaFasa 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07000084

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Mengambil pesertaFasa 2
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06770582

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • City of Hope at Irvine Lennar, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07090499

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Mengambil pesertaFasa 2
  • City of Hope at Irvine Lennar, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07061964

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Mengambil pesertaFasa 1/2
  • UCLA Hematology/Oncology - Irvine, Irvine
  • Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UCI Health - Irvine Infusion Pharmacy ACC, Irvine
  • dan 2 lagi
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07421700

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Mengambil pesertaFasa 3
  • Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07218380

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

Mengambil pesertaFasa 2
  • City of Hope, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT06567743

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Mengambil pesertaFasa 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT07097142

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Mengambil pesertaFasa 1/2
  • University of California - Irvine Medical Center, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Ogo 2026 · NCT04752722

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Mengambil pesertaFasa 2
  • Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • Kaiser Permanente Alton/Sand Canyon Medical Offices, Irvine
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Jul 2026 · NCT04879329

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Mengambil pesertaKajian pemerhatian
  • Massive Bio SYNERGY-AI site, Irvine
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Kajian Kanser Pundi Kencing di bandar lain

Kajian lain di Irvine

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.